CN114634489B - 结晶形式 - Google Patents

结晶形式 Download PDF

Info

Publication number
CN114634489B
CN114634489B CN202210409814.5A CN202210409814A CN114634489B CN 114634489 B CN114634489 B CN 114634489B CN 202210409814 A CN202210409814 A CN 202210409814A CN 114634489 B CN114634489 B CN 114634489B
Authority
CN
China
Prior art keywords
compound
formula
adduct
crystalline form
qtx125
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210409814.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114634489A (zh
Inventor
约苏·扬·巴拉·萨拉萨尔
埃内克·阿尔达瓦·阿雷瓦洛
T·贝洛·伊格莱西亚斯
L·西蒙·布埃拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimatryx SL
Original Assignee
Quimatryx SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimatryx SL filed Critical Quimatryx SL
Priority to CN202210409814.5A priority Critical patent/CN114634489B/zh
Priority to EP22727849.6A priority patent/EP4511124A1/en
Priority to PCT/EP2022/062061 priority patent/WO2023202787A1/en
Priority to JP2024561794A priority patent/JP2025514066A/ja
Priority to US18/858,116 priority patent/US20260070895A1/en
Priority to TW111117204A priority patent/TWI850657B/zh
Publication of CN114634489A publication Critical patent/CN114634489A/zh
Application granted granted Critical
Publication of CN114634489B publication Critical patent/CN114634489B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)
CN202210409814.5A 2022-04-19 2022-04-19 结晶形式 Active CN114634489B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202210409814.5A CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式
EP22727849.6A EP4511124A1 (en) 2022-04-19 2022-05-04 Crystalline forms
PCT/EP2022/062061 WO2023202787A1 (en) 2022-04-19 2022-05-04 Crystalline forms
JP2024561794A JP2025514066A (ja) 2022-04-19 2022-05-04 結晶形
US18/858,116 US20260070895A1 (en) 2022-04-19 2022-05-04 Crystalline forms
TW111117204A TWI850657B (zh) 2022-04-19 2022-05-06 結晶形式

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210409814.5A CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式

Publications (2)

Publication Number Publication Date
CN114634489A CN114634489A (zh) 2022-06-17
CN114634489B true CN114634489B (zh) 2023-07-04

Family

ID=81940491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210409814.5A Active CN114634489B (zh) 2022-04-19 2022-04-19 结晶形式

Country Status (6)

Country Link
US (1) US20260070895A1 (https=)
EP (1) EP4511124A1 (https=)
JP (1) JP2025514066A (https=)
CN (1) CN114634489B (https=)
TW (1) TWI850657B (https=)
WO (1) WO2023202787A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
AR053046A1 (es) * 2005-04-07 2007-04-18 Teijin Pharma Ltd Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
EP3327007B1 (en) * 2015-07-24 2020-06-03 Shenzhen Zhenxing Medical Technology Co., Ltd. Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN107759600A (zh) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
EP3318256A1 (en) 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
AU2020259100B2 (en) * 2019-04-17 2024-12-12 Fundación Kertor 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors

Also Published As

Publication number Publication date
TWI850657B (zh) 2024-08-01
EP4511124A1 (en) 2025-02-26
CN114634489A (zh) 2022-06-17
US20260070895A1 (en) 2026-03-12
JP2025514066A (ja) 2025-05-02
TW202342460A (zh) 2023-11-01
WO2023202787A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US10519176B2 (en) Crystalline forms
ES2525423T3 (es) Nuevos derivados de poliquinolinas y su utilización terapéutica
ES2229342T3 (es) Sales de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona(=ziprasidona),su preparacion y uso como antagonista de dopamina d2.
US20100022783A1 (en) Cyclohexanecarboxylic acid compound
CA3060121A1 (en) Polymorphic form of compound, preparation method and use thereof
EP3784649B1 (en) Process for the synthesis of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
JPWO2020138481A1 (ja) ピロリジン化合物の結晶
CA2890194A1 (en) Amine salts of laquinimod
US20260042792A1 (en) Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof
WO2021026011A1 (en) Solid-state forms of relugolix
JP2025538506A (ja) がんの治療のための縮合ピリジンの固体形態
CN114634489B (zh) 结晶形式
JP2020534331A (ja) （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
KR20230141899A (ko) [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
US11434235B2 (en) Solid form of dihydropyrimidine compound and preparation method therefor and use thereof
HK40066780B (en) Crystalline forms
CN120040450A (zh) 磷酸肌醇3激酶(pi3k)抑制剂的结晶形式
CA2164296C (en) Heterocyclic chemistry
JP2024500665A (ja) ２－ヒドロキシ－５－［２－（４－（トリフルオロメチルフェニル）エチルアミノ）］安息香酸結晶形およびこの製造方法
HK40066780A (zh) 结晶形式
WO2006086773A2 (en) Polyamine analogs as modulators of cell migration and cell motility
JP6656505B2 (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
JPS63295561A (ja) ２−キノロン誘導体
JP2020519624A (ja) Ｌ−オルニチンフェニルアセテートを製造する方法
CA1233471A (en) Acylaminophenol derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066780

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20220617

Assignee: Hongxing Xianghe (Taicang) Biotechnology Co.,Ltd.

Assignor: Quematrix Co.,Ltd.

Contract record no.: X2024990000400

Denomination of invention: Crystalline form

Granted publication date: 20230704

License type: Exclusive License

Record date: 20240802